EXPERT LOGIN
__________________
The Cytonet Group is an international biotechnology company with locations in Weinheim and Heidelberg in Germany and in Durham, North Carolina in the U.S. The company develops, produces and markets cell therapeutic products, including human liver cells.  Cytonet’s goal is to  provide alternatives to existing therapies for many diseases with a particular emphasis on liver diseases.   Cytonet is a pioneer and leader in the field of regenerative medicine. Through the development of novel approaches to treatment we are helping to shape the future of medicine.


  • FIRST DATA ON CYONET’S LIVER CELL THERAPY FOR UREA CYCLE DISORDERS PRESENTED AT THE ANNUAL MEETING OF THE SOCIETY FOR INHERITED METABOLIC DISORDERS (SIMD)
    Weinheim, Germany and Raleigh-Durham, NC, March 10, 2014 – Interim data on the use of liver cell therapy (LCT) for the treatment of pediatric patients with Urea ...  read on

  • CYTONET SUBMITS EUROPEAN APPROVAL APPLICATION FOR LIVER CELL THERAPY TO TREAT UREA CYCLE DISORDERS IN CHILDREN
    Weinheim/Germany, January, 2014 – International biotechnology firm Cytonet announced today that the European Medicines Agency (EMA) has validated its Marketing Authorization Application (MAA) seeking approval for its ...  read on

  • Liver cell therapy: Urea cycle defects – SELICA-clinical trial program
    In December 2013, Cytonet cleared a further vital hurdle – it submitted liver cell therapy for the treatment of congenital urea cycle defects to the European Medicines ...  read on

  • Cure the Cycle Challenge
    The Cure the Cycle Challenge is an annual event, comprising a full day bike ride through Napa Valley. Participants in the Challenge raise money and awareness ...  read on

  • HOME PRESS CONTACT MEDIA VIDEOS CONTACT LEGAL NOTICE